—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Bristol-Myers Squibb Company (BMY) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BMY, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.39 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How BMY has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.39 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Bristol-Myers Squibb Company moved 0.39% on average · correlation 0.14 · higher than 38% of US names
  • Beta, last 3 months 0.51 about the same as over the year
  • On the 10 worst bond days −0.75% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.57% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BMY on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Bristol-Myers Squibb Company

BMY in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bristol-Myers Squibb researches, makes and sells prescription medicines worldwide, covering cancer, blood disorders, immune disease, heart disease and brain conditions. Its portfolio spans older blockbuster drugs such as Eliquis and Revlimid alongside newer immuno-oncology and cell-therapy treatments like Opdivo and Breyanzi, plus recent launches in psoriasis, schizophrenia and lung cancer. It sells through wholesalers, distributors, specialty pharmacies, hospitals and government agencies rather than directly to patients.
Where it sits in the stack
Bristol-Myers Squibb carries no seat in our Rubin AI build-out index; it sits in the diary's broader universe under Healthcare, in the drug manufacturing sleeve alongside other large branded pharmaceutical makers.
Who it is priced against
Closelooknet's peer group is not defined for this name; the market commonly compares it with Pfizer and Merck as fellow diversified branded-drug makers.
Why Closelooknet tracks it
Bristol-Myers Squibb is an S&P 500 constituent but holds no Closelooknet score yet and no Rubin or Halo seat; the diary has not quoted it in an edition so far.
What the diary watches
Whether revenue from newer oncology and immunology launches grows fast enough to offset the older drugs in the portfolio losing exclusivity.

Bristol-Myers Squibb Company (BMY) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: BMY news on the tape · index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Leerink, 2026-10-05

The Street on this name

Analyst actions and the latest print for BMY from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Leerink — target 59 Target set to $59 (+0% to spot) 2026-10-05

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 4.23%, quarterly · last 0.63 USD on 2026-10-02

Dividends and capital return

What BMY pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 2.52 USD per share · a 4.23% yield on the 2026-10-06 close 4 distributions, paid quarterly 2026-10-06
  • Change on the year +1.6% against the prior twelve months prior twelve months 2.48 USD per share
  • Last distribution 0.63 USD per share as the price series records it, within days of the ex-date 2026-10-02
  • By calendar year 2024: 2.40 USD · 2025: 2.48 USD · 2026: 2.52 USD to date first distribution recorded in the three-year window: 2024-01-04

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Bristol-Myers Squibb Company (BMY)?

Bristol-Myers Squibb Company trades as BMY on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is BMY in a Closelooknet index?

Not currently — Bristol-Myers Squibb Company is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does BMY trade against its moving averages?

Pullback inside an uptrend stack: Trades -7.3% vs the 50-day and +0.7% vs the 200-day average, 13.2% below the 52-week high and +43.3% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Bristol-Myers Squibb Company compare with its peers?

Against its peer group (Drug Manufacturers - General · US), Bristol-Myers Squibb Company (BMY) sits 13.2% below its 52-week high, 7.3% below its 50-day average; Amgen Inc (AMGN) is 9.9% below, AbbVie Inc (ABBV) is 1.0% below, Gilead Sciences Inc (GILD) is 7.8% below. Put any of them next to BMY in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Bristol-Myers Squibb Company trade when bond yields rise?

Over the past year Bristol-Myers Squibb Company had a beta of 0.39 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 38% of US names. On the 10 sessions in which long bonds fell most it moved −0.75% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Bristol-Myers Squibb Company do?

Bristol-Myers Squibb researches, makes and sells prescription medicines worldwide, covering cancer, blood disorders, immune disease, heart disease and brain conditions. Its portfolio spans older blockbuster drugs such as Eliquis and Revlimid alongside newer immuno-oncology and cell-therapy treatments like Opdivo and Breyanzi, plus recent launches in psoriasis, schizophrenia and lung cancer. It sells through wholesalers, distributors, specialty pharmacies, hospitals and government agencies rather than directly to patients. Closelooknet's peer group is not defined for this name; the market commonly compares it with Pfizer and Merck as fellow diversified branded-drug makers.

Where does Bristol-Myers Squibb Company sit in the AI build-out?

Bristol-Myers Squibb carries no seat in our Rubin AI build-out index; it sits in the diary's broader universe under Healthcare, in the drug manufacturing sleeve alongside other large branded pharmaceutical makers. Bristol-Myers Squibb is an S&P 500 constituent but holds no Closelooknet score yet and no Rubin or Halo seat; the diary has not quoted it in an edition so far.

Does Bristol-Myers Squibb Company pay a dividend?

Bristol-Myers Squibb Company has paid 2.52 USD per share over the last twelve months, paid quarterly, a trailing yield of 4.23% on the 2026-10-06 close; the last distribution recorded in the price series was 0.63 USD on 2026-10-02. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Bristol-Myers Squibb Company recently?

The most recent analyst action on Bristol-Myers Squibb Company on the Closelooknet wire is a price target by Leerink on 2026-10-05 (target 59). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BMY, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.